Sequence-related vesicular acetylcholine transporter (VAChT) and vesicular monoamine transporter (VMAT) transport neurotransmitter substrates into secretory vesicles. This review seeks to identify shared and differentiated aspects of the transport mechanisms. VAChT and VMAT exchange two protons per substrate molecule with very similar initial velocity kinetics and pH dependencies. However, vesicular gradients of ACh in vivo are much smaller than the driving force for uptake and vesicular gradients of monoamines, suggesting the existence of a regulatory mechanism in ACh storage not found in monoamine storage. The importance of microscopic rather than macroscopic kinetics in structure-function analysis is described. Transporter regions affecting binding or translocation of substrates, inhibitors, and protons have been found with photoaffinity labeling, chimeras, and single-site mutations. VAChT and VMAT exhibit partial structural and mechanistic homology with lactose permease, which belongs to the same sequence-defined superfamily, despite opposite directions of substrate transport. The vesicular transporters translocate the first proton using homologous aspartates in putative transmembrane domain X (ten), but they translocate the second proton using unknown residues that might not be conserved between them. Comparative analysis of the VAChT and VMAT transport mechanisms will aid understanding of regulation in neurotransmitter storage.-Parsons, S. M. Transport mechanisms in acetylcholine and monoamine storage. FASEB
BACKGROUND
At least two components of secretory vesicles are important in storage of classical neurotransmitters. The first is vacuolar ATPase, which pumps protons from cytoplasm to the inside of secretory vesicles. The second is a transporter that exchanges vesicular protons for cytoplasmic neurotransmitter. This review focuses on the kinetic and chemical mechanisms of transport by the vesicular acetylcholine transporter (VAChT) and the vesicular monoamine transporter (VMAT). Transported monoamines include dopamine, norepinephrine, epinephrine, serotonin, and histamine. The monoamine stored by a particular cell type is determined by the monoamine available. The review compares VAChT and VMAT with each other and related lactose permease. It points out similarities among them, as well as differences, in an effort to identify shared and differentiated aspects of the VAChT and VMAT transport mechanisms. Some older data are reinterpreted in light of recent findings.
VMATs arising from different genes (endocrine VMAT1 and neuronal VMAT2) and VAChT have been cloned from species ranging from Caenorhabditis elegans and Drosophila to humans (1) (2) (3) (4) (5) . The predicted amino acid sequences are consistent with 12 transmembrane domains (TMDs, Fig. 1 ). Although the review assumes that 12 TMDs are present, little direct work testing the model has been conducted. Many residues in or near every putative TMD are conserved across VMAT1, VMAT2, and VAChT, suggesting similar structures for TMDs and mechanisms of transport. VMAT isoforms appear to be similar enough to each other in transport mechanisms that they will not be distinguished except when important, and the terms vesicle and granule are used interchangeably.
The physical chemistry of uptake and storage
This topic is well reviewed (6 -11) , and important points are summarized without primary references. The values of transmembrane pH and electrical gradients (⌬pH and ⌬⌿, respectively) are about Ϫ1.4 pH units and ϩ39 mV, respectively, for filled cholinergic and monoaminergic secretory vesicles in situ. The effects of different ⌬pH and ⌬⌿ values on equilibrium gradients of monoamines in vitro demonstrate that VMAT exchanges two protons for each monoamine of plus-1 charge taken up. The esti-mated driving force for monoamine uptake in vivo is 630-fold from ⌬pH and 4.8-fold from ⌬⌿ for a total 3000-fold in equilibrium activity gradient. The exchange stoichiometry and resulting driving force for ACh uptake were not explicitly determined until recently (see below).
The concentration of cytoplasmic monoamines in nerve terminals is in the low M range. The concentration in secretory vesicles is ϳ10,000-fold higher. Because the concentration gradient is larger than the predicted activity gradient, monoamines in vivo historically were assumed to be in equilibrium with vesicular ⌬pH and ⌬⌿. The excess concentration gradient is due to stabilization of stored monoamines by intravesicular association, which lowers activity. However, the extent of stabilization is not known accurately and recent evidence suggests that equilibrium often is not attained (see below).
Pharmacology
A large family of inhibitory compounds is known for VAChT (12, 13) . The lead compound vesamicol binds to the cytoplasmic side (14) with an equilibrium dissociation constant (K D ) value of ϳ5 nM (15) . Binding sometimes exhibits positive cooperativity, but this is a variable observation (16, 17) . Vesamicol analogs inhibit transport noncompetitively (16, 18) , but they apparently need bind only a fraction of VAChT in isolated vesicles to inhibit fully (19) . Addition of vesamicol to vesicles after uptake of [ 3 H]ACh stimulates release of much of the recently transported ACh but not the endogenous ACh (20) .
The significance of these complexities in the effects of vesamicol is unknown. The vesamicol dissociation constant is insensitive to 'energization' of vesicles (establishment of ⌬pH or ⌬⌿). Comparison of their structure-activity relationships suggests that vesamicol and ACh bind to different sites in VAChT, even though the molecules compete with each other for binding at equilibrium (16) . Three major inhibitory compounds are known for VMAT. Reserpine binds to the cytoplasmic side (21) with a K D value of 25-340 nM. This decreases to ϳ30 pM when vesicles are energized (22) (23) (24) (25) . Monoamines inhibit the increase in reserpine affinity with IC 50 values (in the presence of ATP) similar to their transport Michaelis constant (K m ) values (22, 25, 26) . The similarity suggests that substrates and reserpine compete for the same form of VMAT, probably because reserpine is a dead-end inhibitor in the first translocation step of the transport cycle (see below). High-affinity reserpine binding to mutants indicates that the first translocation step is intact, even if the mutation blocks steady-state transport. Ketanserin and tetrabenazine also are potent inhibitors of VMAT. Energization has no affect on their dissociation constants (27, 28) .
Relative values for substrate K D , K m , and V max are distinctive Binding and initial velocity transport of substrates exhibit hyperbolic saturation. VAChT binds ACh with a K D value 10-to 100-fold larger than the K m value of 0.3-1 mM (16, 29, 30) . VMAT likewise binds monoamines with K D values 10-to 100-fold larger than the corresponding K m values of 1-10 M (24, Figure 1 . VAChT and VMAT consensus sequences. Sequences were aligned by BLAST. A residue not exhibiting consensus within a transporter type is indicated by a dash (-), a gap in alignment by a period and the positions before and after the sequence by asterisks, except that Drosophila and C. elegans VAChT sequences continue further toward the carboxyl terminus than shown. Possible transmembrane domains (TMDs) are shaded in gray and labeled. Amino and carboxyl termini probably are cytoplasmic. Residues conserved across both transporters are bold face and highlighted in blue, and residues having a direct or possible indirect role in proton translocation are highlighted in red. Residues in uppercase are totally conserved and those in lowercase are substantially (Ͼ 2/3) conserved. K-D ion pairs are connected by long blue dashes, and possible interactions with the D translocating the first proton are indicated by short red dashes. 31) . Different values of K D and K m can arise from a single binding site when at least one catalytic rate constant is a major contributor to K m . The K m will be smaller than K D when uptake of the occupied binding site for substrate is fast relative to reappearance of the unoccupied binding site during transport (see below).
VAChT transports ACh and large synthetic analogs of ACh with the same V max values (32, 33) . It does not significantly transport choline and monoamines (34) . VMAT likewise transports different monoamines and synthetic substrates with the same V max values (35) (36) (37) (38) (39) . Because the amount of damage to vesicles caused by isolation differs in different preparations, the same preparation must be used to compare V max values for different substrates (33, 40) . Substrate-independent V max suggests that a substrate-independent step in the transport cycle is rate-limiting. This probably is reappearance of the unoccupied binding site for substrate in the last step of the cycle, which is consistent with a small K m /K D ratio. A report that V max for dopamine exceeds that of serotonin by three-to fivefold in cloned VMAT is not reconciled with this conclusion (41) .
Effects of pH reveal important titratable residues
When the amount of binding or transport by inhibitors and substrates is plotted vs. pH, bell-shaped curves often are obtained that reflect two protonation events. The events are of particular interest because they might be related to proton antiport sites. The data tell us more than usually noted. When external pH is varied under standard transport conditions, internal pH varies relatively little due to 'clamping' by vacuolar ATPase activity, which is nearly constant over the pH range typically studied (42) . When a large effect of external pH on transport occurs, it likely arises from protonation of an external transporter site. In an equilibrium binding measurement, one does not know whether a pH effect arises from the inside or outside because pH is the same on both sides of the membrane. However, because all of the equilibrium effects are present in transport measurements, all pH effects reviewed in this section probably occur from the outside.
Transport of subsaturating ACh requires deprotonation with pK a 7.3 and protonation with pK a 9 (16) . Because a change in either V max or K m alters transport rate in subsaturating substrate (as rate Ϸ [substrate o ]V max /K m ), these data do not determine whether V max or K m is affected by pH. Equilibrium binding of vesamicol or a high-affinity synthetic analog of ACh requires deprotonation with pK a 7.1 and 7.4, respectively (43) (44) (45) . Vesamicol binding also requires protonation with pK a Ͼ 9. However, protonated vesamicol itself (which is a tertiary amine) has a similar pK a value. Whether an additional protonation in VAChT is required to bind vesamicol is undetermined.
Transport of subsaturating serotonin requires VMAT deprotonation with pK a 7.1 and protonation with pK a 9 (46) . The V max is approximately constant from pH 6.5 to 8.5 and then decreases at higher pH with pK a 9.0 to 9.5. K m decreases as pH increases with pK a 7.1-7.4 in most experiments (35, 36, 42, 47, 48 2) Two pathways for proton translocation exist in each transporter (see Recent Results for further evidence on VAChT). By analogy to lactose permease (below), an acidic amino acid in each pathway probably moves between aqueous luminal and cytoplasmic exposures to bind and release a proton, respectively. Because protons would move preferentially through much of the transporter in a likely aqueous transport channel or channels, a proton 'wire' passing protons from amino acid to amino acid probably does not operate.
3) If it reorients, the residue of pK a 7.1-7.4 could translocate the second proton. Alternatively, it could interact (for example, as an ion pair) with a separate translocation site for the second proton. This residue is unlikely to be the first proton translocation site, because that site probably is inwardly oriented when substrate binds (below).
4)
With the possible exception of the residue of pK a 7.1-7.4, proton translocation sites have pK a Ͻ 6.5 in the outward orientation. This is because other proton translocation sites do not reveal themselves in these pH studies, which implies that they are essentially fully deprotonated above pH 6.5.
5) An unidentified external residue with pK a Ն 9 controls proton translocation, but it does so indirectly. It cannot itself translocate a proton because the required protonation state is not compatible with antiport.
RECENT RESULTS

The exchange stoichiometry for VAChT
The equilibrium approach to determining exchange stoichiometry has not worked for VAChT. An alternative procedure using a 'pH jump' has. After quickly raising pH o , vesicles equilibrated at acidic pH in the absence of ATP take up ACh until ⌬pH collapses (49) . The time courses of uptake at different pH o , initial pH i and [ACh o ] contain information about microscopic rate and equilibrium dissociation constants. Microscopic constants apply to elementary steps in a kinetic mechanism, whereas the macroscopic constants V max and K m apply to net steadystate behavior composed of many microscopic steps. A microscopic kinetic mechanism restricts the range of allowed chemical mechanisms much more than the macroscopic kinetic mechanism does.
Numerically integrated differential equations describing the two-proton exchange mechanism shown in Fig. 2 fit the data much better than similar equations for one-proton mechanisms (43) . A more positive ⌬⌿ generated with K o ϩ -valinomycin at the same initial pH i stimulates pH jump uptake, and permeant anions like chloride, which convert ⌬⌿ to ⌬pH, stimulate ATPase-driven uptake (43, 50 -52) . Both observations imply that at least two protons are exchanged per molecule of ACh. The distinctive macroscopic kinetics reviewed in the Background section (K m Ͻ Ͻ K D , substrate-independent V max , and similar pK a values) imply that the microscopic kinetic mechanisms for VAChT and VMAT are very similar to each other. Thus, all direct and indirect evidence supports a two-proton exchange mechanism for VAChT.
Characteristics of the microscopic constants
Estimated values of the microscopic constants for VAChT are listed in Table 1 . Their important characteristics are 1) the k 2 step is rate-limiting, 2) ACh i binds weakly, and 3) pK a1 controlling the k 1 step is lower than pK a2 controlling the k 2 step. The value of pK a1 is low enough that it would not have been observed in previous experiments.
The mathematical relationships between macroscopic and microscopic kinetic constants have been derived (16, 43) . They simplify to The VMAT transport cycle also has been modeled as in Fig. 2 (10, 53) , but the values for most of the ) orientations. This is a minimal mechanism that assumes that a single residue controls both NT ϩ binding and proton translocation in the k 2 step. It does not specify whether control is direct or indirect, which is a chemical issue. Potential random binding order for protons and NT ϩ , the requirement for protonation of an external site with pK a Ն 9, and the effect of ⌬⌿ are ignored.
corresponding microscopic constants have not been estimated. They probably are similar to those in Table 1 because of the extensive similarities in the macroscopic kinetics of VMAT and VAChT. Also, K m for VMAT increases when pH i increases (42) . This indicates that k 1 Ј decreases more than k 2 Ј does at higher pH i , which happens when pK a1 Ͻ pK a2 . Thus, VMAT has the same rank order in pK a1 and pK a2 as VAChT does.
Computer simulation indicates that greater than 98% of the substrate binding site in VAChT is outwardly oriented and distributed among the top species in Fig. 2 when no proton gradient is present (43) . That is why macroscopic K D is essentially equal to microscopic K Do Ј. In contrast, the substrate binding site in resting VMAT sometimes has been thought to be inwardly oriented (25) . However, the similarity in VAChT and VMAT kinetics suggests that it, too, prefers the outward orientation. This in turn implies that the energization-dependent increase in reserpine affinity monitors translocation of the first proton as reserpine forms a dead-end complex.
Microscopic constants are very important to structure-function analysis
Because k 2 Ј/k 1 Ј is 0.01 to 0.1 (depending on animal species and pH), VAChT exists mostly as T i .H iϩ during active transport with half-saturating ACh o (Fig. 2) . This pseudo-trapping of an intermediate derived from ACh-bound transporter is what causes K m to be 10-to 100-fold smaller than K D . Moreover, slow k 2 has the following additional consequence. A mutation might decrease k 1 by 10-fold. This would increase K m by 10-fold with no significant effect on V max , even though the mutation has nothing to do with the ACh binding site! Perturbation of K m by a mutation does not necessarily mean that the ACh binding site has been affected. VMAT probably exhibits the same type of behavior. Some published data suffer this ambiguity.
The predicted macroscopic consequences of a change in the value of each microscopic constant are given in Table 2 . Functional mutants (below) can be analyzed using the table. The input information is the effect of a mutation on 1) macroscopic K D (estimated by substrate competition against binding of subsaturating radiolabeled inhibitor in the absence of ATP), 2) macroscopic K m and V max (estimated from initial velocity steady-state transport kinetics using radiolabeled substrate, with V max normalized to the amount of mutant by B max or Western blot), and 3) pK a2 (which is both macroscopic and microscopic and estimated from pH effects on binding of subsaturating radiolabeled inhibitor in the absence of ATP). The output deduction is the microscopic step affected by the mutation. For example, a similar fold decrease in K m and V max with no change in K D and pK a2 likely is due to the same fold decrease in k 2 . All possible combinations of mutant effects lead to a unique microscopic deduction, except when K m alone changes. This result leaves k 1 and pK a1 entangled, but pH jump studies can separate them. Microscopic analysis of mutant effects is important if specific amino acids are to be reliably correlated with specific functions.
Microscopic analysis provides another important caution. If a mutation moderately affecting k 2 was screened for transport using a subsaturating concentration of radiolabeled substrate, the mutation would appear to be a null due to cancellation of effects on V max and K m (above). Some published data suffer this ambiguity. Screening of mutants should be done with substrate concentrations that are low and high relative to the wild-type K m to avoid missing effects.
Thermodynamics constrains regulation of storage
Physiological observations demonstrating that storage of both ACh and monoamines is regulated at the level of the secretory vesicle are reviewed elsewhere (54 -58). Fundamental thermodynamic constraints 
a The table applies to VAChT and probably VMAT. If a mutation alters the value for a microscopic constant (corresponding to Fig. 2 ) in the direction indicated by a column heading (for example, Microscopic constant increases: K Do ), it will change the values of macroscopic constants K D , K M , and V max as indicated by the symbols on that line (1, 1 and -, for the example) . The symbol-means no change, 1 means an increase, and 2 means a decrease.
b A large decrease would be required. c Mutations causing a moderate decrease in value are assumed. If greater than 10-to 100-fold, then V max decreases also.
d Assay at optimal pH 7.8 is assumed.
to such regulation will be discussed here. The ACh concentration in nerve terminal cytoplasm is low mM and consistent with the K m value for vesicular transport. ACh in synaptic vesicles is ϳ100-fold more concentrated (7) . Because ⌬pH and ⌬⌿ values and the exchange stoichiometries are the same for VAChT and VMAT, the driving forces for uptake are the same. Thus, the vesicular gradient of ACh concentration in vivo is 30-fold smaller than the driving force of 3000-fold. Why might this be? One possible reason is that equilibrium would produce an impossible, grossly hyperosmotic concentration of vesicular ACh (over 3 M). This limitation does not exist for VMAT, as the concentrations of cytoplasmic monoamines are 100-fold lower. These observations lead to the hypothesis that down-regulation terminates ACh storage well short of theoretical equilibrium. The consequent excess in driving force would buffer storage against a drop in the concentration of cytoplasmic ACh and allow vesicles to fill at nearly the initial velocity throughout the storage process (43) . Regulation can affect the rate and final amount of storage differently. Because they make serotonin and histamine and express VMAT2, mast cells store serotonin and histamine in the same secretory granules. Mutant cells isolated from knockout heterozygotes expressing one-half of the normal amount of VMAT2 and wild-type cells incubated in tetrabenazine secrete (and thus store) substantially less serotonin but nearly normal or increased amounts of histamine compared to untreated wild-type cells (59) . Yet the storage rates for serotonin and histamine presumably were 'regulated' identically by the manipulations.
Different rates of neurotransmitter leakage explain the results. Intragranular histamine leaks slowly due to protonation of the imidazole ring, and the histamine gradient thus reaches equilibrium with the driving force. As equilibria are not affected by changes in catalyst activity, regulation of VMAT2 has little effect on histamine storage. In contrast, intragranular serotonin leaks rapidly, as do the rest of the monoamines except for histamine (38, 39, 60) . The serotonin gradient thus reaches only a steady state that responds to changes in the rate of uptake.
The results of the mast cell study have the following implications for ACh storage. The existence of vesicular regulation confirms the absence of equilibrium with the initial velocity driving force. As no evidence exists that intravesicular ACh leaks fast enough to limit storage to 1/30th of equilibrium, cholinergic vesicles probably regulate storage by a novel mechanism not found in monoaminergic vesicles.
Structure-function analysis
Because VAChT and VMAT have similar initial velocity transport kinetics and probably have similar TMD packing, available structure-function data for them will be merged in an effort to construct a preliminary model for the chemical mechanism of transport. The certitude of the result is subject to two reservations. Alteration of transporter function by chemical reaction or mutation could arise from propagated conformational change, and macroscopic kinetics can be misleading when not interpreted microscopically (above). The one-letter abbreviations for amino acids will be used to identify specific residues.
Protein chemistry
Organomercurials and methylmethanethiosulfonate react with Torpedo VAChT to reveal an ACh-protected cysteine that is readily accessible after modification. Another reactive cysteine is not protected by ACh. Both residues are protected by vesamicol, suggesting that vesamicol induces widespread conformational change (61) . Identification of the reactive cysteines should help localize the ACh binding site.
Vesamicol binding to Torpedo VAChT is inhibited rapidly by histidine-selective diethylpyrocarbonate, and the rate of the reaction is slowed by vesamicol but not ACh (45) . The conformation of the reactive histidine was proposed to change on protonation.
Photoaffinity labeling
Photoaffinity analogs of ketanserin and tetrabenazine covalently label the NH 2 terminus of VMAT just before TMD I and in loop X/XI (62, 63) . The results suggest that these regions of the sequence are close to each other in inhibited VMAT.
Mutations affecting apparent ligand binding or energy coupling
Recombinant mutants of VAChT and VMAT have been expressed and characterized primarily in vacuolar membranes of mammalian cell lines. Only those mutants exhibiting perturbations of function larger than errors and that inform binding and transport mechanisms will be discussed. A K residue in TMD II and four D residues in TMDs I, VI, X, and XI are conserved in all wild-type VAChTs and VMATs (Fig.  1) . Their presence in hydrophobic environments suggests that these normally charged residues have special functions and thus have been subjected to special scrutiny.
Chimeras
VMAT1 exhibits higher K m values for monoamines, particularly histamine, and a higher K D value for tetrabenazine than VMAT2 does (64) . K m and K D values for chimeras of VMAT1 and VMAT2 suggest that multiple regions affect apparent affinities (65, 66) . A chimera composed of human VMAT2 from the NH 2 terminus up to the beginning of TMD II and human VAChT in the rest of the sequence exhibited sevenfold higher K m for ACh but retained normal vesamicol binding. Thus, part of the ACh binding site might be in a conserved region before TMD II, namely, in TMD I, and the vesamicol binding site lies beyond the beginning of TMD II (67) .
Single-site substitutions
Perturbing mutations that express are summarized in (69, 70) . SSS at end of TMD III Affects serotonin binding and histamine transport by rVMAT2 (AFs-sY-), mutations retain energy coupling to reserpine (68, 71) . D in TMD IV Essential to ACh release from nerve terminal (72) . Unimportant to ACh transport; N weakens vesamicol binding 10-fold (30) . P in TMD V Affects apparent affinity of rVMAT2 (VGpPf) for histamine (73) . A in loop VII/VIII Affects apparent affinity of rVMAT2 (EP-LP) for tetrabenazine and tryptamine but not histamine and probably not serotonin (73) . K in loop VII/VIII E increases apparent affinity of rVMAT2 (s-kwq) for histamine in low-affinity histamine background (73) .
H in TMD VIII
Might form ion pair with D in TMD X in VAChT because a double charge-removing mutation destroys vesamicol binding and the double reversed mutation restores it. A or K transports, C or R does not (70) . D in TMD X Most mutations destroy transport, coupling of reserpine binding to energization and vesamicol binding (30, 46, 72, 69) . Might form ion pair with H in TMD VIII of VAChT (70) . E transports ACh but doesn't bind vesamicol (30) , transports monoamines with altered pH dependence and binds reserpine and tetrabenazine (46) . H in loop X/XI C or R does not transport or couple energy to reserpine (74) . Not important in rVAChT to transport but affects vesamicol binding (70) .
D in TMD XI
Forms ion pair with K in TMD II and promotes serotonin binding. Ion pair is dispensable in VMAT (46, 69) , but it is important in VAChT to transport (30) . N and E block ACh transport with no effect on vesamicol binding. N reduces ACh affinity 10-fold (30) . Y in end of TMD XI F increases apparent affinity of rVMAT2 (-gfAi) for tryptamine and reduces apparent affinity for tetrabenazine, histamine, and serotonin but not dopamine. A increases apparent affinity for serotonin, dopamine, and tryptamine (41, 65) . A in loop XI/XII Affects apparent affinity of rVMAT2 (gGaiv) for serotonin but not tetrabenazine and histamine (41) . K in loop XI/XII Affects apparent affinity of rVMAT2 (ivKai) for tetrabenazine and serotonin but not histamine (41, 65) . D in TMD XII Affects apparent affinity of rVMAT2 (vI-il) for tetrabenazine, histamine, and serotonin but not dopamine (41, 65) . F at end of TMD XII Affects apparent affinity of rVMAT2 (ilyAP) for serotonin but not tetrabenazine (41, 65) .
a The table includes data for VAChT and VMAT. When the position of the mutation is not obvious in Fig. 1 , the underlined mutation site and surrounding sequence from Fig. 1 are given in parentheses. for the first proton (Fig. 1) . The S and C mutations in VMAT destroy transport and coupling of reserpine binding to energization. The E mutation transports, and it is the only mutation in VAChT and VMAT for which pH effects have been determined. The results illustrate the power of pH studies to reveal important features of mutant behavior not otherwise observable. The pH activity curve for transport of subsaturating monoamine is very steep in the pH 7.3-7.6 range, which means that deprotonation of two external sites with pK a values in this pH range is required for transport. The second, newly observed site (in addition to the wild-type site of pK a 7.1-7.4) must be either unimportant or not present in wild type. A simple explanation is that the mutant E residue itself accounts for the new pK a and the pK a for wild-type D is cryptic at Ͻ 6.5. The E mutation also perturbs the pK a for required external protonation, with the new value being ϳ8. Whether the mutation decreases the pK a of the group in wild type that is Ն 9 or unmasks a different group is unknown (46) . D in TMD X of VAChT has similar properties (30) . The residue might be modified by dicyclohexylcarbodiimide (75, 76) .
A dispensable ion pair between K in TMD II and D in TMD XI is present in VMAT, because double mutants substituting another ion pair or charge removal can transport whereas mutants retaining only one of the charges cannot (46, 69) . In VAChT, a positively charged residue is required at the position of K in TMD II for transport, consistent with an ion pair, but charge-removing and charge-exchanged double mutants do not transport (30, 70) . This behavior is consistent with but does not require a proton translocation role for D in TMD XI of VAChT. However, if proton translocation sites are conserved between VAChT and VMAT, then this residue cannot be one (see below). Possibly the K-D ion pair is more critical to structure in VAChT than it is in VMAT. The observations indicate that TMDs II and XI contact each other.
D or E at the position of D in TMD I of VMAT is critical to serotonin binding, and the E mutant transports subsaturating serotonin about one-third as well as wild type does. The transport-incompetent N mutant retains coupling of reserpine binding to energization, indicating that translocation of the first proton is intact (68) . The residue is not critical to transport by VAChT, which is consistent with binding of serotonin and ACh to separate sites (30) . Again, if proton translocation sites are conserved between VAChT and VMAT, then this residue cannot be one (see below). All other aspartates in cytoplasmic domains and TMDs are individually not critical to transport, including completely conserved D in TMD VI (30, 69) .
An H in loop X/XI is the only completely conserved H in VMAT (Fig. 1) . Mutation to R or C destroys transport and coupling of reserpine binding to energization without affecting low-affinity reserpine binding (74) . The latter observation indicates that the tested mutations disrupt translocation of the first proton. Modification of histidine or arginine groups in VMAT by classical protein chemistry has similar effects (77) , and a conserved R also is in loop X/XI (Fig. 1) . However, mutation of this H in rVAChT does not affect transport, although it affects vesamicol binding (70) . The residue in Torpedo VAChT is Y. If it is conserved between VAChT and VMAT, the other proton translocation site cannot be this residue either (see below). An H in TMD VIII is the only completely conserved H in VAChT (Fig. 1 ). Mutation to A or K does not block transport (although C or R does) and a conserved Y is present in VMAT (70) . This H cannot be a proton translocation site per se. It might form an ion pair with D in TMD X, because the double mutation reversing these residues restores vesamicol binding lost in a double mutation removing the charges. It has been speculated to be the site of pK a 7.1 in VAChT (45) . None of the remaining histidines in rVAChT apparently affect transport (70) .
Vectorial relationships in the major facilitator superfamily
VAChT and VMAT are members of the major facilitator superfamily defined by sequence homology (78) . The superfamily includes proton antiporters and symporters. How can small changes in amino acid sequence produce apparently fundamental change in the vectorial relationship of protons and substrate? A transporter architecture containing 1) two truncated channels leading to opposite sides of the membrane and 2) a rotating domain that binds and moves a proton and substrate molecule between the channels can explain this (79) . Binding of the proton and substrate on the opposite or same sides of the rotating domain generates antiport and symport, respectively (Fig. 3) .
Mapping VAChT and VMAT into the lactose permease paradigm
Lactose permease from Escherichia coli is the most studied member of the major facilitator superfamily. It contains 12 helical TMDs for which packing is substantially described from analysis of near neighbors. Most of the TMDs pack circumferentially around TMD VII to form a central transport region (80) . Can lactose permease inform structure-function analysis of VAChT and VMAT, even though it is a proton symporter? Alignment of VAChT and VMAT sequences with the lactose permease se-quence by the BLAST computer program reveals homology (26% identity in the best case) from the beginning of TMD II to the center of TMD V. Is additional structural and mechanistic homology also present? To address this question, the assumed TMDs of VAChT and VMAT were packed similarly to the current model of lactose permease, except that helix tilt was ignored for clarity (Fig. 4) . Tilt brings some helices closer together than apparent in Fig. 4 , for example, VIII and X (81) and II and XI (82) . Use of lactose permease as a folding template is consistent with the principle that secondary and supersecondary structures in a protein family are more highly conserved than primary sequence is.
Only six residues in lactose permease are irreplaceable for transport, and they all occur in TMDs. They are E 126 (TMD IV) and R 144 (TMD V) in the lactose binding site; E 269 (TMD VIII), R 302 (TMD IX) and H 322 (TMD X) probably in a net-neutral triad; and E 325 (TMD X), which has pK a Ͼ 10, possibly because it faces the low dielectric interior of the membrane. To begin a transport cycle, a periplasmic proton binds to E 325 . Periplasmic lactose then binds. A conformational change propagated from the occupied lactose binding site disrupts the triad and releases R 302 . This in turn promotes rotation of TMD X so that E 325 can form an ion pair with R
302
. The isomerized ternary complex releases lactose and the proton to cytoplasm to complete the first half of the transport cycle. Empty transporter spontaneously relaxes back to the original state to finish the cycle (83) .
Although the amount of data allowing comparison of TMD packing in VAChT and VMAT with that in lactose permease is limited, the sequence homology and ion-pairing inferences provide evidence spanning most of the TMDs (namely, TMDs II-V, VIII, X, and XI) that the packing patterns are similar. No evidence conflicts. Thus, single-site mutations affecting the properties of VAChT and VMAT are mapped into Fig. 4 assuming that protons, substrates, and inhibitors bind to a central transport region. An interesting picture emerges that suggests lactose permease and the rotating-domain model can inform analyses of VAChT and VMAT at coarse levels of structure and function.
Components in the chemical mechanism of transport
E
325 and D in TMD X are located similarly, and they each translocate a proton to cytoplasm. If it acts analogously to E 325 , D in TMD X translocates the first proton in the VAChT and VMAT transport cycles. The pK a of the site is ϳ4.7 (Table 1) , which is nearly normal and consistent with the deduction in the Background that the pK a is cryptic in standard transport assays. The large difference in pK a values for E 325 and D in TMD X does not imply different roles for the residues, as pK a can be altered by local environment without altering fundamental mechanism.
TMDs I-III, XI, and XII and the adjacent loops probably contain binding sites for ACh and each monoamine that are separate from but close to each other, as most of the mutations affecting apparent substrate binding occur in this region (Fig. 4 and above). Because most of these mutations are in the half of the putative architecture proximal to lumen, substrate binding probably occurs deep in the transport channel. Also, the putative neurotransmitter binding sites lie largely away from the lactose binding site toward the opposite side of TMD VII. Such a lateral change in location of substrate binding coincident with a switch from symport to antiport evokes the rotating-domain model. If TMDs VII and X act in concert as a rotating domain, a lactose permease-like conformational change controlled by protonation of Helix tilt is not shown in this oblique view from the cytoplasmic face (80, 81) . Mutations described in Table 3 are assumed to lie toward a central transport region. A mutation affecting apparent affinity for a substrate is indicated by a green spot or edge. A mutation affecting inhibitor binding is indicated by yellow. Mutated residues linked directly or indirectly to proton translocation are indicated by red, with the residue in TMD X the only fully conserved such residue. A TMD residue is labeled with the Roman numeral of the TMD, and a residue in an inter-TMD loop is labeled with the Roman numerals of the flanking TMDs. Intense color indicates that the residue can be seen directly, whereas pale color indicates that one or two TMDs lie in the line of sight. D in TMD X might mediate the first translocation step in the VAChT and VMAT transport cycles. The values of the rate constants for the 'k 1 ' steps in VAChT and lactose permease are similar (84) .
VAChT and VMAT must use microscopic steps that are different from those of lactose permease in the second half of the transport cycle to translocate another proton. The final steps must be difficult, as VAChT turns over ϳ10-fold more slowly than lactose permease does (84) . No candidate for another proton translocation site conserved between VAChT and VMAT has been identified. Possibly the second site is not conserved.
As discussed above, H in loop X/XI and D in TMD I of VMAT as well as D in TMD XI of VAChT each have an attribute expected of a proton translocation site. However, they also suffer problems in this role. The H in VMAT appears to be linked to translocation of the first proton, but this proton was assigned to D in TMD X and the assignment seems well supported. Moreover, the residue probably is not in contact with luminal protons (Fig. 4) . Possibly it modulates and does not mediate proton translocation. All three of the residues have homologues apparently not important to function in the other transporter type. This odd behavior implies that these residues have undiscovered differentiating interactions. As no well-supported candidate for the second proton translocation site has been identified for either VAChT or VMAT, discussion of chemical mechanism for the remainder of the transport cycle is premature.
Finally, sites linked to binding of vesamicol, ketanserin, and tetrabenazine by photoaffinity labeling or mutation are distributed widely (Fig. 4 and above) . The dispersal suggests that binding of inhibitors causes widespread conformational change. Possibly binding of protons to the site of pK a 7.1-7.4 causes similar widespread conformational change.
MATTERS OF CONTROVERSY AND UNANSWERED QUESTIONS
Many corresponding aspects of the VAChT and VMAT transport mechanisms are even more similar to each other than formerly recognized. The exchange stoichiometries, driving forces for uptake, characteristics of macroscopic and inferred microscopic kinetics, and important pK a values are very similar, and D residues in TMD X are important in both transporters. Nevertheless, differences exist in the importance of homologous aspartates and histidines for unclear reasons.
The largest unknowns surely are the tertiary structures of VAChT and VMAT. Unfortunately, even a low-resolution structure is not forthcoming. In the absence of one, it would be useful to test further whether 12 TMDs indeed are present and packed similarly to those in lactose permease. Until more substantial structural information is available, the components of chemical mechanism hypothesized here must be regarded as speculative. The comparison of VAChT and VMAT with lactose permease is heuristic. It is intended to aid conceptual organization of a large body of data, and it will change as more data accumulate.
Evidence for regulation in the storage of classical neurotransmitters is accumulating. However, the important difference between regulation of rates and final amounts, and the role that thermodynamics plays in regulation, have not been sufficiently recognized and characterized. The hypothesis that the final amount of ACh storage is regulated by a novel mechanism appears robust because it is based on large discrepancies with monoamine storage and the driving force. However, the existence of regulation in ACh storage is controversial because only a few workers have obtained direct evidence consistent with the idea. New physiological tests will be welcomed.
Progress in understanding the VAChT and VMAT transport mechanisms would be facilitated by microscopic interpretation of the effects of mutations and many more pH studies. Particularly needed are assignments of observed pK a values to specific residues acting in specific steps and identification of the second proton translocation site. Also needed are better localization of substrate binding sites, descriptions of the conformational steps returning VAChT and VMAT to the beginning of their respective transport cycles, and comprehensive models for regulation of VAChT and VMAT activities. A lot of work remains!
PROSPECTS AND PREDICTIONS
Comparative analysis of the VAChT and VMAT transport mechanisms will lay the foundation for understanding their regulation. Regulation of ACh storage probably lies within VAChT, at least in part, because no evidence exists for down-regulation of ⌬pH or ⌬⌿ by the amount required to explain a 30-fold storage shortfall. The mechanistic and regulatory insights gained could lead to new treatments for neurological disorders by control of neurotransmitter storage.
